ACTICCA-1
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care (currently in stage 2 capecitabine) after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1). A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial.
III
interventionell
International
Gemcitabin, Cisplatin
Status: In Rekrutierung
Zeitraum
2014
Zentren
50
60
Keine Zentren gesucht
Patienten
781
699
19.04.2022
Klinische Settings
II, III
adjuvant
1st line
kurativ
Beteiligte
AIO-Arbeitsgruppen
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Förderer
Deutsche Krebshilfe, medac GmbH (Germany), Cancer Research UK, KWF Kanker Bestrijding The Netherlands, AGITG Australia
Identifier
AIO-HEP-0112
AIO-HEP-0112
2012-005078-70